EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PBT2 potentiates carbapenem antibiotics against diverse Klebsiella pneumoniae strains

Aimee Tan iD, Abigail R Hartono iD, Adam P Gunn iD, Claire L Gorrie iD, David M P De Oliveira iD, Francesca L Short iD, Mark J Walker iD, Norelle L Sherry iD, Benjamin P Howden iD, Christopher A McDevitt iD

Microbiology Spectrum · 03.11.2026 · 14 (11)

DOI: 10.1128/spectrum.02109-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 03.11.2026. Verfasst von Aimee Tan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Au…. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Carbapenems, Anti-Bacterial Agents. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHMRC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Carbapenem-resistant Klebsiella pneumoniae is recognized by the World Health Organization as a critical priority for urgent antimicrobial development. Due to the lack of novel antimicrobial classes in the development pipeline, this study investigated the application of an antibiotic potentiator, the zinc ionophore PBT2, to restore the utility of critical antibiotics. The data show that zinc and PBT2 can increase the sensitivity of diverse clinical strains of K. pneumoniae to carbapenem antibiotics, including those strains containing metallo-β-lactamases and porin mutations. PBT2 induced zinc and iron dyshomeostasis in these strains, resulting in altered uptake of multiple antimicrobial agents. Furthermore, PBT2 exposure also decreased resistance to agents, including ethanol and hydrogen peroxide, and reduced the potential for horizontal gene mobilization. Collectively, these impacts on metal homeostasis and cell composition suggest that PBT2 may have potential as an adjunct therapy for the treatment of multidrug-resistant K. pneumoniae . IMPORTANCE Carbapenem-resistant Klebsiella pneumoniae is a major nosocomial threat and a top World Health Organization priority for urgent antimicrobial development. Resistance can be mediated by multiple classes of mobilizable carbapenemase enzymes, with varied treatment recommendations, depending on which class is present. This work describes how a repurposed drug called PBT2 can potentiate carbapenem activity against a clinical K. pneumoniae panel, independent of resistance mechanism. This could support the development of PBT2 as a broad-spectrum potentiator compound against drug-resistant K. pneumoniae .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Klebsiella pneumoniaeCarbapenemsAnti-Bacterial AgentsKlebsiella InfectionsMicrobial Sensitivity TestsHumansPorinsbeta-LactamasesDrug SynergismZincBacterial ProteinsDrug Resistance, Multiple, BacterialCarbapenem-Resistant Enterobacteriaceae

Stichwörter der Autor:innen

ESKAPEKlebsiellaantibiotic resistanceantimicrobialcarbapenemionophoretherapeutic

Substanzen

CarbapenemsAnti-Bacterial AgentsPorinsbeta-LactamasesZincBacterial Proteins

Autor:innen und Institutionen

  • Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia.
  • Centre for Pathogen Genomics, University of Melbourne, Melbourne, Victoria, Australia.
  • Microbiological Diagnostic Unit (MDU) Public Health Laboratory, Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australi…
  • Centre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia.
  • Department of Microbiology, Infection Program, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
  • Department of Infectious Diseases and Immunology, Austin Health, Heidelberg, Victoria, Australia.

ORCID-Profile: Aimee Tan, Abigail R Hartono, Adam P Gunn, Claire L Gorrie, David M P De Oliveira, Francesca L Short, Mark J Walker, Norelle L Sherry, Benjamin P Howden, Christopher A McDevitt

Förderung

  • NHMRC

Zitieren

APA

Tan, A., Hartono, A. R., Gunn, A. P., Gorrie, C. L., De Oliveira, D. M. P., Short, F. L., Walker, M. J., Sherry, N. L., Howden, B. P., & McDevitt, C. A. (2026). PBT2 potentiates carbapenem antibiotics against diverse Klebsiella pneumoniae strains. Microbiology Spectrum, 14(11). https://doi.org/10.1128/spectrum.02109-26

Vancouver

Tan A, Hartono AR, Gunn AP, Gorrie CL, De Oliveira DMP, Short FL, et al. PBT2 potentiates carbapenem antibiotics against diverse Klebsiella pneumoniae strains. Microbiology Spectrum. 2026;14(11). doi:10.1128/spectrum.02109-26

BibTeX
@article{Tan2026,
  author = {Tan, Aimee and Hartono, Abigail R and Gunn, Adam P and Gorrie, Claire L and De Oliveira, David M P and Short, Francesca L and Walker, Mark J and Sherry, Norelle L and Howden, Benjamin P and McDevitt, Christopher A},
  title = {PBT2 potentiates carbapenem antibiotics against diverse Klebsiella pneumoniae strains},
  journal = {Microbiology Spectrum},
  year = {2026},
  volume = {14},
  number = {11},
  doi = {10.1128/spectrum.02109-26}
}
Kostenlos starten →